Analysis on the expressions of serum IgE, FcεRI and their antibodies in patients with benign thyroid diseases

doi:10.3969/j.issn.1673-8640.2015.05.010

Abstract

Abstract: Objective To analyze the expressions of immunoglobulin E (IgE), FcεRIα and their antibodies in serum from patients with benign thyroid diseases and investigate their relationships with benign thyroid diseases. Methods A total of 41 Graves' disease (GD) patients, 36 Hashimoto's thyroiditis (HT) patients, 36 thyroid nodule (TN) patients and 60 healthy subjects were enrolled. The expressions of FcεRIα, anti-IgE antibody and anti-FcεRI antibody were determined by competitive enzyme-linked immunosorbent assay (ELISA), and the level of IgE was determined by rate nephelometry. Their differences in 4 groups and their relationships with benign thyroid diseases were analyzed. Results The levels of IgE in GD, HT and TN groups had no statistical significance compared with that in healthy control group (P>0.05). The serum levels of FcεRIα and anti-IgE antibody in GD, HT and TN groups were higher than that in healthy control group (P<0.05). The level of anti-FcεRI antibody in GD group was higher than that in healthy control group. The relationships of the serum levels of IgE, FcεRIα, anti-IgE antibody and anti-FcεRI antibody with thyroid hormone autoantibody (TRAb) were not observed in HT or TN group, but there was a negative correlation of serum FcεRIα with TRAb (r_s=-0.350, P<0.05), and there was a positive positive correlation of anti-IgE and anti-FcεRI antibodies with TRAb in GD group (r_s=0.546 and 0.520, P<0.05). Conclusions There are high expressions of serum IgE, FcεRIα and their antibodies in patients with benign thyroid diseases and a significant correlation of them with TRAb in GD group. The results suggest that these antibodies may participate in the occurrence and progress of benign thyroid diseases.

Key words: Immunoglobulin E, FcεRIα, Anti-immunoglobulin E, Anti-FcεRI, Thyroid disease

CLC Number:

R446.1

WANG Yuping, CUI Zelin, LIN Lihui, WANG Juan, LI Jia, PENG Xia, XIE Guogang, LI Li. Analysis on the expressions of serum IgE, FcεRI and their antibodies in patients with benign thyroid diseases[J]. Laboratory Medicine, 2015, 30(5): 450-453.

Figures/Tables 3

References 11

[1]	王斌,彭文晖.良性甲状腺疾病手术治疗的临床分析[J].中国医药指南,2014,12(26):198.
[2]	MOSHKELGOSHA S, SO PW, DEASY N, et al.Cutting edge:retrobulbar inflammation,adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves'orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation[J].Endocrinology,2013,154(9):3008-3015.
[3]	中华医学会内分泌学会《中国甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南——甲状腺结节[J].中华内科杂志,2008,47(10):867-968.
[4]	SEGNI M, PUCARELLI I, TRUGLIA S,et al.High prevalence of antinuclear antibodies in children with thyroid autoimmunity[J].J Immunol Res,2014,2014:150239.
[5]	TURKOGLU Z, ZINDANCI I, TURKOGLU O, et al.Skin autoreactivity in Hashimoto's thyroiditis patients without urticaria: autologous serum skin test positivity correlation with thyroid antibodies, sonographical volume and grading[J].Eur J Dermatol,2012,22(3):345-350.
[6]	DOUTRE MS.Chronic urticaria and thyroid auto-immunity[J].Clin Rev Allergy Immunol,2006,30(1):31-37.
[7]	PLATZER B, RUITER F, VAN DER MEE J, et al.Soluble IgE receptors-elements of the IgE network[J].Immunol Lett,2011,141(1):36-44.
[8]	MOLNÉR I. What is the role of allergic sensitization in Graves' disease[J].Orv Hetil,2007,148(29):1347-1352.
[9]	MARONE G,SPADARO G,PALUMBO C,et al.The anti-IgE/anti-Fcepsilon Rlalpha autoantibody network in allergic and autoimmune diseases[J].Clin Exp Allergy,1999,29(1):17-27.
[10]	MACNEIL AJ, YANG YJ, LIN TJ.MAPK kinase 3 specifically regulates Fc epsilonRI-mediated IL-4 production by mast cells[J]. J Immunol,2011,187(6):3374-3382.
[11]	SUZUKI R, LEACH S, LIU W,et al.Molecular editing of cellular responses by the high-affinity receptor for IgE[J].Science,2014,343(6174):1021-1025.

组别	FT3(pmol/L)	FT4(pmol/L)	TT3(nmol/L)	TT4(nmol/L)	TSH(μIU/mL)
GD组	14.6(7.7,29.1)^*	50.2(19.9,83.1)^*	4.9(2.0,7.7)^*	212.8(126.9,283.0)^*	0.04(0.01,0.09)^*
HT组	4.8(4.2,11.9)	19.4(15.7,32.9)^*	1.6(1.3,2.5)	115.5(94.8,155.6)	2.10(0.04,8.80)
TN组	4.4(4.2,5.0)	17.3(15.0,19.7)	1.4(1.2,1.6)	102.7(91.8,125.8)	1.80(1.10,3.30)
正常对照组	4.5(4.0,5.0)	16.6(15.4,19.9)	1.5(1.2,1.6)	107.3(91.9,126.7)	1.84(1.28,2.47)
组别	rT3(nmol/L)	Tg(ng/mL)	TPOAb(IU/mL)	TRAb(IU/L)	A-TG(IU/mL)
GD组	1.6(0.8,2.3)^*	20.0(16.7,28.8)^*	87.5(16.2,335.5)^*	7.2(3.3,19.4)^*	55.0(25.0,511.0)^*
HT组	1.0(0.9,1.2)^*	19.7(15.0,22.8)^*	275.3(90.2,561.3)^*	0.6(0.3,13.4)^*	633.4(254.0,1 219.0)^*
TN组	0.7(0.6,0.9)	8.4(7.3,12.3)	8.5(5.0,13.2)	0.5(0.3,0.7)	12.8(10.0,27.3)
正常对照组	0.7(0.6,0.8)	7.5(6.4,8.6)	7.7(5.4,11.8)	0.4(0.3,0.6)	11.0(10.0,25.7)

组别	FT3(pmol/L)	FT4(pmol/L)	TT3(nmol/L)	TT4(nmol/L)	TSH(μIU/mL)
GD组	14.6(7.7,29.1)^*	50.2(19.9,83.1)^*	4.9(2.0,7.7)^*	212.8(126.9,283.0)^*	0.04(0.01,0.09)^*
HT组	4.8(4.2,11.9)	19.4(15.7,32.9)^*	1.6(1.3,2.5)	115.5(94.8,155.6)	2.10(0.04,8.80)
TN组	4.4(4.2,5.0)	17.3(15.0,19.7)	1.4(1.2,1.6)	102.7(91.8,125.8)	1.80(1.10,3.30)
正常对照组	4.5(4.0,5.0)	16.6(15.4,19.9)	1.5(1.2,1.6)	107.3(91.9,126.7)	1.84(1.28,2.47)
组别	rT3(nmol/L)	Tg(ng/mL)	TPOAb(IU/mL)	TRAb(IU/L)	A-TG(IU/mL)
GD组	1.6(0.8,2.3)^*	20.0(16.7,28.8)^*	87.5(16.2,335.5)^*	7.2(3.3,19.4)^*	55.0(25.0,511.0)^*
HT组	1.0(0.9,1.2)^*	19.7(15.0,22.8)^*	275.3(90.2,561.3)^*	0.6(0.3,13.4)^*	633.4(254.0,1 219.0)^*
TN组	0.7(0.6,0.9)	8.4(7.3,12.3)	8.5(5.0,13.2)	0.5(0.3,0.7)	12.8(10.0,27.3)
正常对照组	0.7(0.6,0.8)	7.5(6.4,8.6)	7.7(5.4,11.8)	0.4(0.3,0.6)	11.0(10.0,25.7)

组别	IgE(IU/mL)	FcεRIα(μg/mL)	抗IgE抗体(μg/mL)	抗FcεRI抗体(μg/mL)
GD组	48.3(24.0,219.0)	6.7(4.2,9.9)^*	2.4(1.5,4.9)^*	61.8(42.8,104.0)^*
HT组	44.0(19.4,91.4)	5.5(3.3,8.2)^*	1.4(0.8,3.1)^*	41.6(27.6,65.7)
TN组	44.7(20.9,99.0)	7.7(5.2,9.9)^*	1.5(1.0,1.9)^*	43.5(33.0,52.5)
正常对照组	31.8(17.5,95.0)	2.8(1.7,6.2)	1.0(0.8,1.2)	36.7(29.6,44.4)

组别	IgE(IU/mL)	FcεRIα(μg/mL)	抗IgE抗体(μg/mL)	抗FcεRI抗体(μg/mL)
GD组	48.3(24.0,219.0)	6.7(4.2,9.9)^*	2.4(1.5,4.9)^*	61.8(42.8,104.0)^*
HT组	44.0(19.4,91.4)	5.5(3.3,8.2)^*	1.4(0.8,3.1)^*	41.6(27.6,65.7)
TN组	44.7(20.9,99.0)	7.7(5.2,9.9)^*	1.5(1.0,1.9)^*	43.5(33.0,52.5)
正常对照组	31.8(17.5,95.0)	2.8(1.7,6.2)	1.0(0.8,1.2)	36.7(29.6,44.4)

项目	TPOAb	A-TG	TRAb
IgE	0.177	-0.178	0.229
FcεRIα	-0.024	-0.350	0.052
抗IgE抗体	-0.018	-0.120	0.546
抗FcεRI抗体	0.125	-0.018	0.520